Table 2.
Clinicopathologic characteristics of patients stratified by both neoadjuvant and adjuvant chemotherapy
| Parameters | With preoperative chemotherapy (n = 122) | P value | Without preoperative chemotherapy (n = 142) | P value | ||
|---|---|---|---|---|---|---|
| With ACT (n, %) | Without ACT (n, %) | With ACT (n, %) | Without ACT (n, %) | |||
| Number of patients | 98 | 24 | 102 | 40 | ||
| Age, years | ||||||
| ≤ 60 | 69 (70.4) | 16 (66.7) | 0.721 | 60 (58.8) | 19 (47.5) | 0.222 |
| > 60 | 29 (29.6) | 8 (33.3) | 42 (41.2) | 21 (52.5) | ||
| Sex | ||||||
| Male | 65 (66.3) | 17 (70.8) | 0.673 | 63 (61.8) | 26 (65.0) | 0.720 |
| Female | 33 (33.7) | 7 (29.2) | 39 (38.2) | 14 (35.0) | ||
| Primary tumor location | ||||||
| Colon | 55 (56.1) | 15 (62.5) | 0.571 | 71 (69.6) | 22 (55.0) | 0.100 |
| Rectum | 43 (43.9) | 9 (37.5) | 31 (30.4) | 18 (45.0) | ||
| Primary tumor differentiation | ||||||
| Well to moderate | 72 (73.5) | 20 (83.3) | 0.315 | 83 (81.4) | 31 (77.5) | 0.602 |
| Poor | 26 (26.5) | 4 (16.7) | 19 (18.6) | 9 (22.5) | ||
| T stagea | ||||||
| 1–3 | 50 (53.2) | 12 (54.5) | 0.909 | 72 (77.4) | 23 (67.6) | 0.261 |
| 4 | 44 (46.8) | 10 (45.5) | 21 (22.6) | 11 (32.4) | ||
| N stageb | ||||||
| 0 | 41 (45.6) | 12 (54.5) | 0.449 | 37 (40.2) | 13 (38.2) | 0.840 |
| 1–2 | 49 (54.4) | 10 (45.5) | 55 (59.8) | 21 (61.8) | ||
| Timing of metastasis | ||||||
| Synchronous | 74 (75.5) | 15 (62.5) | 0.198 | 62 (60.8) | 20 (50.0) | 0.242 |
| Metachronous | 24 (24.5) | 9 (37.5) | 40 (39.2) | 20 (50.0) | ||
| Number of metastatic tumors | ||||||
| 1 | 29 (29.6) | 9 (37.5) | 0.453 | 73 (71.6) | 29 (72.5) | 0.912 |
| 2–5 | 69 (70.4) | 15 (62.5) | 29 (28.4) | 11 (27.5) | ||
| Metastases diameter (cm)c | ||||||
| ≤ 3 | 59 (62.1) | 14 (58.3) | 0.735 | 75 (73.5) | 25 (64.1) | 0.270 |
| > 3 | 36 (37.9) | 10 (41.7) | 27 (26.5) | 14 (35.9) | ||
| Preoperative CEA (ng/mL)d | ||||||
| ≤ 50 | 78 (82.1) | 17 (81.0) | 0.901 | 78 (81.3) | 27 (69.2) | 0.128 |
| > 50 | 17 (17.9) | 4 (19.0) | 18 (18.8) | 12 (30.8) | ||
| Preoperative CA19-9 (U/mL)e | ||||||
| ≤ 35 | 70 (76.9) | 15 (75.0) | 1.000 | 58 (61.1) | 23 (62.2) | 0.906 |
| > 35 | 21 (23.1) | 5 (25.0) | 37 (38.9) | 14 (37.8) | ||
| MSKCC-CRSf | ||||||
| 0–2 | 54 (63.5) | 9 (47.4) | 0.193 | 73 (83.0) | 26 (78.8) | 0.597 |
| 3–5 | 31 (36.5) | 10 (52.6) | 15 (17.0) | 7 (21.2) | ||
| Preoperative chemotherapy regimen | ||||||
| FOLFOX + XELOX | 61 (62.2) | 18 (75.0) | 0.503 | |||
| FOLFIRI | 31 (31.6) | 5 (20.8) | ||||
| Capecitabine | 6 (6.1) | 1 (4.2) | ||||
| Radiological response to preoperative chemotherapyg | ||||||
| PR | 57 (58.8) | 13 (54.2) | 0.683 | |||
| SD | 30 (30.9) | 7 (29.2) | ||||
| PD | 10 (10.3) | 4 (16.7) | ||||
ACT adjuvant chemotherapy, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score, PD progressive disease, PR partial response, SD stable disease
aData were available for 243 patients
bData were available for 238 patients
cData were available for 260 patients
dData were available for 251 patients
eData were available for 243 patients
fData were available for 225 patients
gData were available for 121 patients